{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:01:59Z","timestamp":1769554919816,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Low-barrier to access programs has emerged as a way to overcome the significant hurdles associated with buprenorphine initiation. However, there has been limited research evaluating services set in low-barrier programs outside of buprenorphine. In this issue of the <jats:italic toggle=\"yes\">Journal of Addiction Medicine<\/jats:italic>, Harvey and colleagues evaluate a sexually transmitted and blood-borne infection screening protocol implemented in a low-barrier access program in Boston, Massachusetts. The data supports that infection protocols can be efficiently implemented in the low-barrier setting, yielding high rates of diagnosis, and the potential for decentralized models of treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/adm.0000000000000802","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T08:25:21Z","timestamp":1612599921000},"page":"452-453","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Expanding the Evidence on Integrated Opioid Use Disorder and Infectious Disease Care"],"prefix":"10.1097","volume":"15","author":[{"given":"Sarah","family":"Kattakuzhy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elana","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"issue":"(5)","key":"R1-20250526","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"issue":"(1)","key":"R2-20250526","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","article-title":"Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco","volume":"14","author":"Carter","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"(4)","key":"R3-20250526","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1097\/ADM.0000000000000682","article-title":"Low barrier tele-buprenorphine in the time of COVID-19: a case report","volume":"14","author":"Harris","year":"2020","journal-title":"J Addict Med"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"108011","DOI":"10.1016\/j.jsat.2020.108011","article-title":"Appointment wait-times and arrival for patients at a low-barrier access addiction clinic","volume":"114","author":"Roy","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"(25)","key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cct.2019.02.009","article-title":"A randomized controlled trial of buprenorphine for probationers and parolees: bridging the gap into treatment","volume":"79","author":"Gordon","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"107879","DOI":"10.1016\/j.drugalcdep.2020.107879","article-title":"Effects of interim buprenorphine treatment for opioid use disorder among emerging adults","volume":"208","author":"Peck","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"105779","DOI":"10.1016\/j.ypmed.2019.105779","article-title":"Sexual risk behaviors and STDs among persons who inject drugs: a national study","volume":"126","author":"Brookmeyer","year":"2019","journal-title":"Prev Med"},{"issue":"(11)","key":"R9-20250526","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"(Supplement_2)","key":"R11-20250526","first-page":"S82","volume":"6","author":"Rosenthal","year":"2019","journal-title":"2897 collocated buprenorphine is associated with improved HCV visit adherence in people who inject drugs (PWID): data from the ANCHOR study open forum infectious diseases"},{"issue":"(4)","key":"R12-20250526","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/sti.78.4.292","article-title":"The historical role and education of nurses for the care and management of sexually transmitted infections in the United Kingdom: 1 role","volume":"78","author":"Miles","year":"2002","journal-title":"Sex Transm Infect"},{"issue":"(5)","key":"R13-20250526","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann Intern Med"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drugpo.2019.02.013","article-title":"Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting","volume":"72","author":"Overton","year":"2019","journal-title":"Int J Drug Policy"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T20:03:05Z","timestamp":1748289785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000802","relation":{},"ISSN":["1932-0620","1935-3227"],"issn-type":[{"value":"1932-0620","type":"print"},{"value":"1935-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]}}}